Andes virus mRNA vaccines: comparison of unmodified and modified mRNA platforms

Bukreyev, Alexander; Kuzmin, Ivan; Acosta, Rubén; Wasdin, Perry; Mire, Chad E.; Engdahl, Taylor; Moon, Woohyun J.; Popov, Vsevolod L.; Crowe, James E.; Georgiev, Ivelin S.; García-Blanco, Mariano A.; Abbott, Robert G.

doi:10.21203/rs.3.rs-3182841/v1

Cited by 2 publications

(1 citation statement)

References 92 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used a modified nucleotide (5-methoxyuridine) with the expectation of reduced innate immune responses to improve the expressions of antigens. Bukreyev et al recently reported that mRNA-LNP vaccines against Andes virus with and without modified nucleotides exhibited no significant differences in protection and immunogenicity in a hamster model ( 65 ). Intriguingly, they dephosphorylated IVT-mRNA and removed dsRNA by a method using cellulose.…”

Section: Discussionmentioning

confidence: 99%

An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice

Hashizume,

Takashima,

Iwasaki

2024

J Virol

View full text Add to dashboard Cite

The mammarenavirus Lassa virus (LASV) causes the life-threatening hemorrhagic fever disease, Lassa fever. The lack of licensed medical countermeasures against LASV underscores the urgent need for the development of novel LASV vaccines, which has been hampered by the requirement for a biosafety level 4 facility to handle live LASV. Here, we investigated the efficacy of mRNA-lipid nanoparticle (mRNA-LNP)-based vaccines expressing the LASV glycoprotein precursor (LASgpc) or nucleoprotein (LCMnp) of the prototypic mammarenavirus, lymphocytic choriomeningitis virus (LCMV), in mice. Two doses of LASgpc- or LCMnp-mRNA-LNP administered intravenously (i.v.) protected C57BL/6 mice from a lethal challenge with a recombinant (r) LCMV expressing a modified LASgpc (rLCMV/LASgpc 2m ) inoculated intracranially. Intramuscular (i.m.) immunization with two doses of LASgpc- or LCMnp-mRNA-LNP significantly reduced the viral load in C57BL/6 mice inoculated i.v. with rLCMV/LASgpc 2m . High levels of viremia and lethality were observed in CBA mice inoculated i.v. with rLCMV/LASgpc 2m , which were abrogated by i.m. immunization with two doses of LASgpc-mRNA-LNP. The protective efficacy of two i.m. doses of LCMnp-mRNA-LNP was confirmed in a lethal hemorrhagic disease model of FVB mice i.v. inoculated with wild-type rLCMV. In all conditions tested, negligible and high levels of LASgpc- and LCMnp-specific antibodies were detected in mRNA-LNP-immunized mice, respectively, but robust LASgpc- and LCMnp-specific CD8 + T cell responses were induced. Accordingly, plasma from LASgpc-mRNA-LNP-immunized mice did not exhibit neutralizing activity. Our findings and surrogate mouse models of LASV infection, which can be studied at a reduced biocontainment level, provide a critical foundation for the rapid development of mRNA-LNP-based LASV vaccines. IMPORTANCE Lassa virus (LASV) is a highly pathogenic mammarenavirus responsible for several hundred thousand infections annually in West African countries, causing a high number of lethal Lassa fever (LF) cases. Despite its significant impact on human health, clinically approved, safe, and effective medical countermeasures against LF are not available. The requirement of a biosafety level 4 facility to handle live LASV has been one of the main obstacles to the research and development of LASV countermeasures. Here, we report that two doses of mRNA-lipid nanoparticle-based vaccines expressing the LASV glycoprotein precursor (LASgpc) or nucleoprotein (LCMnp) of lymphocytic choriomeningitis virus (LCMV), a mammarenavirus genetically closely related to LASV, conferred protection to recombinant LCMV-based surrogate mouse models of lethal LASV infection. Notably, robust LASgpc- and LCMnp-specific CD8 + T cell responses were detected in mRNA-LNP-immunized mice, whereas no virus-neutralizing activity was observed.

show abstract

Section: Discussionmentioning

confidence: 99%